Randomized phase II trial of docetaxel/irinotecan and gemcitabine/ irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma, Non-Small-Cell Lung
  • Cyclooxygenase Inhibitors
  • Lung Neoplasms
  • Pyrazoles
  • Sulfonamides

abstract

  • Survival results for the second-line regimens in this study were similar to results reported for single-agent therapy in this setting. CBX did not appear to enhance efficacy or improve patient-reported symptoms. The addition of high-dose CBX to second-line chemotherapy in NSCLC cannot be recommended.

publication date

  • October 20, 2006

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2006.07.4773

PubMed ID

  • 17050867

Additional Document Info

start page

  • 4825

end page

  • 32

volume

  • 24

number

  • 30